Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Nora AI
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

RaySearch Laboratories: RaySearch signs agreement with B dot Medical for development of advanced software solutions for proton therapy

Raysearch Laboratories

RaySearch Laboratories AB (publ) is pleased to announce a strategic collaboration agreement with B dot Medical Inc. aimed at advancing the field of proton therapy by development and validation of intregrations between RaySearch's treatment planning system RayStation®*, oncology information system RayCare®* and B dot Medical's ultra-compact proton therapy system.

B dot Medical is a Japanese company dedicated to the development of an ultra-compact proton therapy system with a non-rotating gantry, which is focused on achieveing exceptional irradiation performance, including cutting-edge features such as high-speed scanning and respiratory-gated irradiation.

The collaboration aims at expanding the accessibility and availability of proton therapy technology to a wide range of healthcare facilities and regions worldwide. Ultimately, the goal is to benefit patients by making proton therapy more accessible.

Takuji Furukawa, President and CEO, B dot Medical, says: "This collaboration represents a significant step forward in our mission, "proton for everyone". By partnering with RaySearch, we can further optimize the capabilities of our systems, bringing innovative solutions to the field of radiation oncology. We are excited about the impact this collaboration will have on patient care and will accelerate our business to expand the market for radiotherapy and propose optimal solutions to hospitals."

Johan Löf, founder and CEO, RaySearch, says: "We are thrilled to join forces with B dot Medical in this groundbreaking collaboration. By combining our respective expertise, we can drive innovation and contribute to the advancement of proton therapy technology. Together, we are committed to improving cancer treatment outcomes and making proton therapy more accessible to patients globally."

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.